Single application of high-intensity focused ultrasound as primary therapy of localized prostate cancer: Treatment-related predictors of biochemical outcomes

被引:6
|
作者
Pfeiffer, Dietrich [1 ]
Berger, Juergen [2 ]
Gross, Andreas [1 ]
机构
[1] Asklepios Hosp Hamburg Barmbek, Dept Urol, Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Ctr Med Expt, Inst Med Biometry & Epidemiol, Hamburg, Germany
关键词
Prostate cancer; High-intensity focused ultrasound; Efficacy; Biochemical failure; Prostate edema; Patient movement;
D O I
10.1016/j.ajur.2014.08.009
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: Recent reports on high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer suggest that preoperative risk groups of tumor recurrence are strong predictors of oncological outcomes. The purpose of this study is to determine the prognostic significance of treatment-related factors in relation to patient characteristics for biochemical outcomes after HIFU. Methods: This retrospective single-center study included patients treated from December 2002 to December 2010 for localized prostate cancer with two generations of Ablatherm (R) HIFU devices (A1 and A2). All the patients underwent single HIFU treatment session under the concept of whole-gland therapy. Prostate surgery was performed before HIFU to downsize enlarged glands. Androgen deprivation therapy (ADT) was discontinued before HIFU. Biochemical failure (BCF) was defined as prostate specific antigen (PSA) nadir + 1.2 ng/mL (Stuttgart definition). Predictors of BCF were determined using Cox regression models. As covariates, patient-related factors (age, tumor characteristics, ADT) were compared with treatment-related factors (prostate volume, HIFU device generation, conduct of therapy, prostate edema, patient movement, anesthetic modalities). Results: Three hundred and twenty-three (98.8%) out of 327 consecutive patients were evaluable for BCF. Median (interquartile range) follow-up was 51.2 (36.6-80.4) months. The overall BCF-rate was 23.8%. In multivariate analyses, higher initial PSA-values (Hazard ratio [HR]: 1.03; p < 0.001) and higher D'Amico risk stages (HR: 3.45; p < 0.001) were patient-related predictors of BCF. Regarding treatment-related factors, the A2 HIFU device was associated with a decreased risk of BCF (HR: 0.51; p Z 0.007), while prostate edema had an adverse effect HR: 1.8; p Z 0.027). Short follow-up and retrospective study design are the primary limitations. Conclusion: Success in a single HIFU session depends not merely on tumor characteristics, but also on treatment-related factors. Ablation is more efficacious with the technically advanced A2 HIFU device. Heat-induced prostate edema might adversely affect the outcome. (C) 2015 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier ( Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license
引用
收藏
页码:46 / 52
页数:7
相关论文
共 50 条
  • [1] Single session of high-intensity focused ultrasound for localized prostate cancer: treatment outcomes and potential effect as a primary therapy
    Komura, Kazumasa
    Inamoto, Teruo
    Takai, Tomoaki
    Uchimoto, Taizo
    Saito, Kenkichi
    Tanda, Naoki
    Kono, Junko
    Minami, Koichiro
    Uehara, Hirohumi
    Fujisue, Yutaka
    Takahara, Kiyoshi
    Hirano, Hajime
    Nomi, Hayahito
    Watsuji, Toshikazu
    Kiyama, Satoshi
    Azuma, Haruhito
    WORLD JOURNAL OF UROLOGY, 2014, 32 (05) : 1339 - 1345
  • [2] Transrectal high-intensity focused ultrasound for treatment of localized prostate cancer
    Inoue, Yoji
    Goto, Keisuke
    Hayashi, Tetsutaro
    Hayashi, Mutsuo
    INTERNATIONAL JOURNAL OF UROLOGY, 2011, 18 (05) : 358 - 363
  • [3] High-intensity focused ultrasound therapy for clinically localized prostate cancer
    H M Lee
    J H Hong
    H Y Choi
    Prostate Cancer and Prostatic Diseases, 2006, 9 : 439 - 443
  • [4] High-intensity focused ultrasound therapy for clinically localized prostate cancer
    Lee, H. M.
    Hong, J. H.
    Choi, H. Y.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2006, 9 (04) : 439 - 443
  • [5] Primary whole-gland ablation for localized prostate cancer with high-intensity focused ultrasound: The important predictors of biochemical recurrence
    Chen, Po Yen
    Chiang, Po Hui
    Liu, Yi Yang
    Chuang, Yao Chi
    Cheng, Yuan Tso
    INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 (06) : 615 - 620
  • [6] Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes
    Emberton, Mark
    BJU INTERNATIONAL, 2012, 110 (11) : 1707 - 1708
  • [7] Treatment of localized prostate cancer using high-intensity focused ultrasound
    Uchida, T
    Ohkusa, H
    Nagata, Y
    Hyodo, T
    Satoh, T
    Irie, A
    BJU INTERNATIONAL, 2006, 97 (01) : 56 - 61
  • [8] High-intensity focused ultrasound therapy for prostate cancer
    Uchida, Toyoaki
    Nakano, Mayura
    Hongo, Satoko
    Shoji, Sunao
    Nagata, Yohishiro
    Satoh, Takefumi
    Baba, Shiro
    Usui, Yukio
    Terachi, Toshiro
    INTERNATIONAL JOURNAL OF UROLOGY, 2012, 19 (03) : 187 - 201
  • [9] High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure
    Blana, Andreas
    Brown, Stephen C. W.
    Chaussy, Christian
    Conti, Giario N.
    Eastham, James A.
    Ganzer, Roman
    Murat, Francois J.
    Pasticier, Gilles
    Rebillard, Xavier
    Rewcastle, John C.
    Robertson, Cary N.
    Thuroff, Stefan
    Ward, John F.
    BJU INTERNATIONAL, 2009, 104 (08) : 1058 - 1062
  • [10] Development and future prospective of treatment for localized prostate cancer with high-intensity focused ultrasound
    Shoji, Sunao
    Koizumi, Norihiro
    Yuzuriha, Soichiro
    Kano, Tatsuo
    Ogawa, Takahiro
    Nakano, Mayura
    Kawakami, Masayoshi
    Nitta, Masahiro
    Hasegawa, Masanori
    Miyajima, Akira
    JOURNAL OF MEDICAL ULTRASONICS, 2022,